Full Program Just Released!
Your Flagship Event Driving ADC Innovation, Insights & Connections

Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Bristol Myers’ $800M bispecific ADC aces China breast cancer study, putting TROP2 drugs on notice
Regeneron pens $2.3B pact with Parabilis to develop new type of ADC-like therapy
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals

Hua Fang

Hua Fang

Scientific Director Abbvie

Seminars

Tuesday 13th October 2026

Exploring the Safety & Efficacy Profile of ABBV-400 in CRC to Assess ADC Impact in Unmet Solid Tumor Medical Need

12:00 pm

Laying out the history and progress made developing ADCs and other therapeutics against c-Met
Detailing the safety and efficacy profile of ABBV-400, focused on CRC and solid tumor indications
Exploring future development plans and potential of ABBV 400 in impact CRC patients currently underserved by ADC therapies

Hua Fang - Speaker at 17th World ADC San Diego Summit

View all Speakers

View Event Brochure